Grandeur Peak Global Advisors LLC Cuts Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

Grandeur Peak Global Advisors LLC trimmed its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 26.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 242,791 shares of the medical device company's stock after selling 86,478 shares during the period. Grandeur Peak Global Advisors LLC owned approximately 0.50% of AtriCure worth $7,420,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Kennedy Capital Management LLC raised its stake in shares of AtriCure by 29.8% during the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after acquiring an additional 172,648 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of AtriCure during the fourth quarter valued at approximately $3,716,000. Norges Bank purchased a new position in shares of AtriCure in the fourth quarter worth $3,421,000. JPMorgan Chase & Co. raised its holdings in AtriCure by 43.1% during the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after buying an additional 110,039 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in AtriCure by 67.1% in the 4th quarter. Renaissance Technologies LLC now owns 163,900 shares of the medical device company's stock worth $5,009,000 after acquiring an additional 65,800 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

Insider Transactions at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Analysts Set New Price Targets

ATRC has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and set a $51.00 price target on shares of AtriCure in a report on Thursday, March 27th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. JMP Securities restated a "market outperform" rating and issued a $60.00 price target on shares of AtriCure in a research note on Monday, February 10th. Oppenheimer increased their target price on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group lowered their price target on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and an average target price of $49.44.

AtriCure Trading Down 0.2 %

Shares of AtriCure stock traded down $0.06 during trading on Thursday, hitting $32.02. The stock had a trading volume of 109,790 shares, compared to its average volume of 656,951. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The firm's fifty day simple moving average is $35.49 and its 200-day simple moving average is $34.31. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11. The stock has a market cap of $1.57 billion, a PE ratio of -33.65 and a beta of 1.65.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.